Company Encyclopedia
View More
name
Nuvectis Pharma
NVCT.US
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc.
1.935 T
NVCT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies

    Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating for Nuvectis Pharma, with a $10.00 price target. The recommendation is driven by promising clinical studies of NXP900, targeting advanced EGFR-mutated NSCLC. The Phase 1b study, broad enrollment criteria, and promising Phase 1a results enhance the stock's outlook. Expected data readouts in 2026 could further support the positive outlook.

    Tip Ranks·
    US
    NVCT
    -7.02%
    Tip Ranks·
    US
    NVCT
    -7.02%

    Nuvectis Pharma Launches Phase 1b Trial of NXP900 and Osimertinib in EGFRmut+ NSCLC

    Nuvectis Pharma Inc. has initiated a Phase 1b clinical trial to evaluate the combination of NXP900 and osimertinib in EGFR-mutated NSCLC patients resistant to osimertinib. The trial aims to assess the safety and clinical activity of this combination. Data readouts are expected in 2026, with updates anticipated throughout the year. The news was published by Nuvectis Pharma via GlobeNewswire on December 17, 2025.

    Reuters·
    US
    NVCT
    -7.02%
    Reuters·
    US
    NVCT
    -7.02%

    Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors

    Nuvectis Pharma Inc. will host a virtual meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in advanced solid tumors, including its combination with osimertinib for non-small cell lung cancer. The event will feature experts and cover key data and strategies, followed by a live Q&A session. A replay will be available on the company's website.

    Reuters·
    US
    NVCT
    -7.02%
    Reuters·
    US
    NVCT
    -7.02%

    Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress

    Naz Rahman from Maxim Group maintains a Buy rating on Nuvectis Pharma with a $17.00 price target, driven by the promising efficacy of NXP900, a Src family kinase inhibitor. The drug is in Phase 1b trials for cancer patients resistant to EGFR and ALK inhibitors. Positive data from a similar drug supports its potential. H.C. Wainwright also reiterated a Buy rating with a $10.00 target.

    Tip Ranks·
    US
    NVCT
    -7.02%
    Tip Ranks·
    US
    NVCT
    -7.02%

    Nuvectis Pharma Executives Make Bold Moves with Major Stock Purchases!

    Nuvectis Pharma executives made significant stock purchases on November 6, 2025, with Chairman & CEO Ron Bentsur buying 5,000 shares, Director Matthew L. Kaplan acquiring 11,000 shares, and Director Juan Sanchez purchasing 13,000 shares. Despite a Q3 net loss of $19.1 million, the company raised capital to $35.4 million and advanced clinical trials. TipRanks’ AI Analyst rates NVCT as Neutral, highlighting high-risk factors and weak financial performance, but notes strong technical indicators. The stock's speculative nature is emphasized due to consistent losses and lack of dividends.

    Tip Ranks·
    US
    NVCT
    -7.02%
    Tip Ranks·
    US
    NVCT
    -7.02%
    © 2025 Longbridge｜Disclaimer